Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-08-30
2005-08-30
Huff, Sheela J. (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023400, C530S387100, C530S387300, C530S387900, C530S387700
Reexamination Certificate
active
06936706
ABSTRACT:
An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the analogue peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analogue peptide of this invention, monoclonal antibodies thereof, Fab, Fab′, (Fab′)2, CDR, variable region, or analogues or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.
REFERENCES:
patent: 4708930 (1987-11-01), Kortright
patent: 5075219 (1991-12-01), Ceriani et al.
patent: 5077220 (1991-12-01), Ceriani et al.
patent: 2 188 638 (1988-10-01), None
patent: WO92/04380 (1992-03-01), None
Kramer, E.L. et al., “Initial Clinical Evaluation of Radiolabeled MX-DTPA Humanized BrE-3 Antibody in Patients with Advanced Breast Cancer”, Clinical Cancer Research, 4:1679-1688, Jul. 1998.
Varhoeyen, et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Science 239: 1534-1536 (Mar. 1988).
Tempest, et al., “Reshaping a Human Monoclonal to Inhibit Human Respiratory Synctial Virus Infection in Vivo”, Biotechnology 9: 266-271 (Mar. 1991).
Peterson, et al., “Biochemical and Histological Characterization of Antigens Preferentially Expressed on the Surface and Cytoplasm of Breast Carcinoma Cells Identified by Monoclonal Antibodies Against the Human Milk Fat Globule”, Hybridoma 9:221-235 (1990).
Davies, D.R. and Padlan, E.A. “Antibody Antigen Complexes”, Annu. Rev. Biochem. 59:439-73 (1990).
Riechmann, L., et al., Reshaping Human Antibodies for Therapy:, Nature 332:323-327 (1988).
Ceriani Roberto L.
Couto Fernando J. R. do
Padlan Eduardo A.
Peterson Jerry A.
Amzel Viviana
Huff Sheela J.
LandOfFree
Modified antibodies with human milk fat globule specificity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified antibodies with human milk fat globule specificity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified antibodies with human milk fat globule specificity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3495426